Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News Acorda Therapeutics Inc. ACOR

Acorda Therapeutics Inc is a biopharmaceutical company focused on developing therapies that restore function and improve the lives of people with neurological disorders. Acorda uses scientific, clinical, and commercial expertise in neurology as strategic points of access in additional nervous system markets, including stroke, Parkinson's disease, and epilepsy. The company does not operate separate lines of business with respect to any of its products or product candidates. All of its net product revenue is derived from the United States.


Recent & Breaking News (NDAQ:ACOR)

Acorda Therapeutics Makes December 2022 $6.2 Million Interest Payment on Secured Debt in Cash

Business Wire 2 days ago

Acorda Therapeutics Announces Passage of Reverse Stock Split Proposal at its Special Meeting of Stockholders

Business Wire November 11, 2022

Acorda Therapeutics Announces Adjournment of Special Meeting of Stockholders

Business Wire November 4, 2022

Acorda Therapeutics Reports Third Quarter 2022 Financial Results

Business Wire November 1, 2022

Acorda Therapeutics Provides Long-Term Business Plan and Financial Guidance

Business Wire October 27, 2022

Acorda Third Quarter 2022 Update: Webcast/Conference Call Scheduled for November 1, 2022

Business Wire October 25, 2022

Acorda Shareholders Invited to Virtual Q&A with CEO Ron Cohen, M.D.

Business Wire October 21, 2022

ISS, Glass Lewis, and Egan-Jones Recommend that Acorda Stockholders Vote FOR the Proposal to Implement a Reverse Stock Split

Business Wire October 19, 2022

Acorda Therapeutics Will Not Use Shares for December 2022 $6.2 Million Interest Payment on Secured Debt

Business Wire October 18, 2022

Acorda Therapeutics Announces $16.5M Award and Royalty/Supply Relief in AMPYRA® Arbitration Case

Business Wire October 16, 2022

Acorda Therapeutics Withdraws Proposal to Increase Authorized Shares from Special Meeting of Stockholders

Business Wire October 10, 2022

Acorda Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference

Business Wire September 8, 2022

Acorda Therapeutics Enters into License Agreement with Asieris Pharmaceuticals

Business Wire August 29, 2022

Acorda Therapeutics Announces Resignation of Chief Operating Officer

Business Wire August 19, 2022

Acorda Therapeutics Reports Second Quarter 2022 Financial Results

Business Wire August 4, 2022

Acorda Second Quarter 2022 Update: Webcast/Conference Call Scheduled for August 4, 2022

Business Wire July 28, 2022

Esteve Launches INBRIJA® in Germany

Business Wire June 16, 2022

Acorda Therapeutics Reports First Quarter 2022 Financial Results

Business Wire May 11, 2022

Acorda Therapeutics and Biopas Laboratories Announce Agreement to Commercialize INBRIJA® in Latin America

Business Wire May 11, 2022

Acorda First Quarter 2022 Update: Webcast/Conference Call Scheduled for May 11, 2022

Business Wire May 4, 2022